The active constituents in cannabis, cannabinoids, have massive impacts on numerous organ networks. Cannabinoids activate two primary receptor forms:
CB1 is mainly found in the central nervous system, meaning the brain and spinal cord. CB2 is primarily found in the immune system. The primary cannabinoids found in cannabis are Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC interacts with CB1 largely. The effect CBD doesn’t come from CB1 or CB2 interaction but, instead, interaction with the peripheral nervous system.
Here is the full scientific article if you wish to download it.
Mammals are also known to make their own cannabinoid-like agents called endocannabinoids. These are found in the endocannabinoid system (ECS). The two best-known endocannabinoids include:
Some impacts of endocannabinoids are not transmissioned through CB1 and CB2 receptors. Recently, the lone G protein-coupled receptor 55 (GPR55) was categorized as a cannabinoid receptor. In the report, two studies showed that GPR55 is communicated in numerous cancer forms. This indicates a cancer biomarker and a plausible therapeutic site.
It has been found the cannabinoid receptor GPR55 promotes cancer cell proliferation. Using cannabioids
The current two research lines suggest that GPR55 supports cancer cell proliferation (increase of cells). In a particular line of research, a scientist (called Andradas) discovered that most human cancer cell lines hold small amounts of GPR55 mRNA. Greater GPR55 communication is related to more troublesome forms of breast tumors, pancreatic tumors, and glioblastomas.
Overcommunication of GPR55 enhanced proliferation of HEK293 cells through extracellular transmissioning the mediated protein kinase. More so, reduction of GRP55 communication in T98G glioma cells decreased tumor development. In other research, GPR55 communication was seen in numerous prostate and ovarian cancer cell tissues. It has now been suggested GPR55 has a massive role in cancer development and triggering of intracellular transmissioning routes.
More so, in prostate cancer cells, the triggering of GPR55 lead to flourishing cell proliferation (increase). In order for cancer to be treated, GPR55 receptors must be minimized through a negative interaction that reduces activity.
Our newfound knowledge on the proliferative impacts of GPR55 on cancer cells improves our understanding of tumor succession. It also advances treatment plans for cancer.
Many cannabinoid solutions have been positively applied for curing neuropathic pain, multiple sclerosis, schizophrenia and a numerous of other syndromes. Cannabinoids have a range of related impacts, including:
Cannabinoid 1 and 2 agonists were recently put forward as treatment for numerous cancer forms. Cannabinoids have been proven effective in eliminating chemotherapy induced nausea, vomiting, and lack of appetite. Synthetic cannabinoids have been chemically engineered for this reason. The most commonly known compound in cannabis, Δ⁹-tetrahydrocannabinol (THC), is the most frequently applied cannabinoid in clinical situations. It has been illustrated to have antitumor effects. These effects are reliant on dose and cell type.
If you want to explore medical cannabis as a possible cancer treatment, you must speak with your doctor and live in a state or country with legalized medical cannabis. As science progresses, we are hopeful laws will to. In the meantime, use the guidance of medical professionals to find the best treatment plan for you. We still require the systematic review offered by clinical trials before we start seeing the use of cannabinoids on cancer a commonplace practice.